Search research articles
Contact Us
Filters
Showing results (171-180 of 206) with videos related to
Page
of 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma
Martin F Kaiser, Andrew Hall, Katrina Walker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
S Stintzing, P Wirapati, H-J Lenz, et al.
Genes, Chromosomes & Cancer
|
October 8, 2014
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma
Eileen M Boyle, Paula Z Proszek, Martin F Kaiser, et al.
Blood
|
August 20, 2025
Challenging the Concept of Functional High-Risk Myeloma through Transcriptional and Genetic Profiling
Sina Alexandra Beer, David A Cairns, Charlotte Pawlyn, et al.
Oncogene
|
January 11, 2019
The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation
Katarzyna Parzych, Paula Saavedra-García, Gabriel N Valbuena, et al.
Cancer Cell
|
November 16, 2010
Hdac3 is essential for the maintenance of chromatin structure and genome stability
Srividya Bhaskara, Sarah K Knutson, Guochun Jiang, et al.
Blood
|
November 18, 2018
The genomic landscape of plasma cells in systemic light chain amyloidosis
Eileen M Boyle, Cody Ashby, Christopher P Wardell, et al.
Blood
|
March 26, 2015
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia
Andrea Kühnl, Peter J M Valk, Mathijs A Sanders, et al.
Leukemia
|
December 2, 2020
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
James Croft, Sidra Ellis, Amy L Sherborne, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 15, 2021
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method
M Haas, D T Waldschmidt, M Stahl, et al.
Page
of 21
Search research articles
Search
Showing results (171-180 of 206) with videos related to
Sort By:
Page
of 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma
Martin F Kaiser, Andrew Hall, Katrina Walker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
S Stintzing, P Wirapati, H-J Lenz, et al.
Genes, Chromosomes & Cancer
|
October 8, 2014
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma
Eileen M Boyle, Paula Z Proszek, Martin F Kaiser, et al.
Blood
|
August 20, 2025
Challenging the Concept of Functional High-Risk Myeloma through Transcriptional and Genetic Profiling
Sina Alexandra Beer, David A Cairns, Charlotte Pawlyn, et al.
Oncogene
|
January 11, 2019
The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation
Katarzyna Parzych, Paula Saavedra-García, Gabriel N Valbuena, et al.
Cancer Cell
|
November 16, 2010
Hdac3 is essential for the maintenance of chromatin structure and genome stability
Srividya Bhaskara, Sarah K Knutson, Guochun Jiang, et al.
Blood
|
November 18, 2018
The genomic landscape of plasma cells in systemic light chain amyloidosis
Eileen M Boyle, Cody Ashby, Christopher P Wardell, et al.
Blood
|
March 26, 2015
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia
Andrea Kühnl, Peter J M Valk, Mathijs A Sanders, et al.
Leukemia
|
December 2, 2020
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
James Croft, Sidra Ellis, Amy L Sherborne, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 15, 2021
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method
M Haas, D T Waldschmidt, M Stahl, et al.
Page
of 21